SuperworthLexeo Therapeutics EPS LXEO
Diluted earnings per share by quarter and over the last twelve months, from 2022.
- Last 12 months, to Jun 30, 2026
- −$1.15
- Latest quarter, Q2 FY26
- −$0.30
- Fiscal year 2025
- −$2.19
Lexeo Therapeutics' earnings per share was −$1.15 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.30.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.19 | n/a |
| FY2024 | −$3.08 | n/a |
| FY2022 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.30 | n/a | −$1.15 | |
| Q1 FY26 | −$0.25 | n/a | −$1.45 | |
| Q4 FY25 | −$0.27 | n/a | −$2.19 | |
| Q3 FY25 | −$0.33 | n/a | −$2.70 | |
| Q2 FY25 | −$0.60 | n/a | −$3.26 | |
| Q1 FY25 | −$0.99 | n/a | −$3.30 | |
| Q4 FY24 | −$0.78 | n/a | −$3.08 | |
| Q3 FY24 | −$0.89 | n/a | n/a | |
| Q2 FY24 | −$0.64 | n/a | n/a | |
| Q1 FY24 | −$0.77 | n/a | n/a | |
| Q3 FY23 | −$12.36 | n/a | −$41.10 | |
| Q2 FY23 | −$8.30 | n/a | −$39.12 |
Against its peers
Companies in Biotechnology nearest Lexeo Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| LXEOLexeo Therapeutics | −$1.15 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| Peer median | $0.46 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Lexeo Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.